Portal de Periódicos da CAPES

Human insulin resistance: the role of glucocorticoids

2003; Wiley; Volume: 5; Issue: 1 Linguagem: Inglês

10.1046/j.1463-1326.2003.00221.x

1463-1326

Rebecca M. Reynolds, Brian R. Walker,

Hormonal Regulation and Hypertension

Diabetes, Obesity and MetabolismVolume 5, Issue 1 p. 5-12 Human insulin resistance: the role of glucocorticoids Rebecca M. Reynolds, Corresponding Author Rebecca M. Reynolds University of Edinburgh, Department of Medical Sciences, Western General Hospital, Edinburgh, UK RMR is a Wellcome Clinical Training Fellow. Dr R. Reynolds, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail:R.Reynolds@ed.ac.ukSearch for more papers by this authorBrian R. Walker, Brian R. Walker University of Edinburgh, Department of Medical Sciences, Western General Hospital, Edinburgh, UK BRW is a British Heart Foundation Senior Research Fellow.Search for more papers by this author Rebecca M. Reynolds, Corresponding Author Rebecca M. Reynolds University of Edinburgh, Department of Medical Sciences, Western General Hospital, Edinburgh, UK RMR is a Wellcome Clinical Training Fellow. Dr R. Reynolds, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail:R.Reynolds@ed.ac.ukSearch for more papers by this authorBrian R. Walker, Brian R. Walker University of Edinburgh, Department of Medical Sciences, Western General Hospital, Edinburgh, UK BRW is a British Heart Foundation Senior Research Fellow.Search for more papers by this author First published: 31 January 2003 https://doi.org/10.1046/j.1463-1326.2003.00221.xCitations: 58 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Kahn CR. Insulin resistance, insulin insensitivity and insulin unresponsiveness: a necessary distinction. Metabolism January 2003; 27: 1893–1902. 2 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607 . 3 Björntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 1991; 230: 195–201. 4 Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23: 1610–1616. 5 Barker DJP, Osmond C, Golding J, Jkuh D, Wadsworth MEJ. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Br Med J 1989; 298: 564–567 . 6 Phillips DEW, Barker DJP, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37: 150–154. 7 Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895–906. 8 Baynes KC, Whitehead J, Krook A, O'Rahilly S. Molecular mechanisms of inherited insulin resistance. Q JM 1997; 90: 557–562. 9 Yoshimura R, Araki E, Ura S et al. Impact of natural IRS-1 mutations on insulin signals: mutations of IRS-1 in the PTB domain and near SH2 protein binding sites result in impaired function at different steps of IRS-1 signaling. Diabetes 1997; 46: 929–936. 10 Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312. 11 Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996; 17: 245–261. 12 Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Colch) 1999; 96: 513–523. 13 Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997; 66: 581–611. 14 Dimitriadis G, Leighton B, Parry-Billings M et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997; 321: 707–712. 15 Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3–10. 16 Delaunay F, Khan A, Cintra A et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997; 100: 2094–2098. 17 Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000; 13: 1155–1160. 18 Watt GCM, Harrap SB, Foy CJW et al. Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four corners approach to the identification of genetic determinants of blood pressure. J Hypertens 1992; 10: 473–482. 19 Filipovsky J, Ducimetiere P, Eschwege E, Richard JL, Rosselin G, Claude JR. The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996; 14: 229–235. 20 Stolk RP, Lamberts SWJ, de Jong FH, Pols HAP, Grobbee DE. Gender differences in the associations between cortisol and insulin sensitivity in healthy subjects. J Endocrinol 1996; 149: 313–318. 21 Walker BR, Phillips DIW, Noon JP et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998; 31: 891–895. 22 Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853–1859. 23 Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell J MC. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999; 3: 1374–1378. 24 Phillips DIW, Barker DJP, Fall CHD et al. Elevated plasma cortisol concentrations: an explanation for the relationship between low birthweight and adult cardiovascular risk factors. J Clin Endocrinol Metab 1998; 83: 757–760. 25 Phillips DI, Walker BR, Reynolds RM et al. Low birthweight predicts elevated plasma cortisol concentrations in adults from three populations. Hypertension 2000; 35: 1301–1306. 26 Reynolds RM, Walker BR, Syddall HE et al. Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. J Clin Endocrinol Metab 2001; 86: 245–250. 27 Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW. Deficient inactivation of cortisol by 11 β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf ) 1993; 39: 221–227. 28 Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25: 67–70. 29 Barker DJP. In Parkinson M, Urquhart J, Brady T eds. Mothers, Babies and Health in Later Life, 2nd edn. Edinburgh: Churchill Livingstone, 1998. 30 Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993; 341: 339–341. 31 Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996; 39: 1299–1305. 32 Langley-Evans SC, Jackson AA. Increased systolic blood pressure in adult rats induced by fetal exposure to maternal low protein diets. Clin Sci 1994; 86: 217–222. 33 Levitt NS, Holmes MC, Lindsay RS, Seckl JR. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology 1996; 64: 412–418. 34 Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 1998; 101: 2174–2181. 35 Clark PM, Hindmarsh PC, Shiell AW, Law CM, Honour JW, Barker DJP. Size at birth and adrenocortical function in childhood. Clin Endocrinol 1996; 45: 721–726. 36 Harland PSEG, Watson MJ, Ashworth L. The effect of metabolic programming on atherosclerosis and obesity risk factors in UK adolescents living in poor socioeconomic areas. Ann N Y Acad Sci 1997; 817: 361–364. 37 Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl JR. Impaired glucose tolerance and elevated blood pressure in low birthweight, nonobese, young South African adults: early programming of cortisol axis. J Clin Endocrinol Metab 2000; 85: 4611–4618. 38 Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41: 882–886. 39 Pasquali R, Cantobelli S, Casimirri F et al. The hypothalamic–pituitary–adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993; 77: 341–346. 40 Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose–response study. Obes Res 1996; 4: 277–282. 41 Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83: 1806–1809. 42 Strain GW, Zumoff B, Strain JJ. Cortisol production in obesity. Metabolism Clin Exp 1980; 29: 980–985. 43 Lottenberg S, Giannella-Neto D, Derendorf H et al. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 1998; 36: 501–505. 44 Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 alpha-reductase activity in polycystic ovary syndrome. Lancet 1990; 335: 431–433. 45 Liddle GW. Tests of pituitary adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20: 1539–1560. 46 Meijer OC, de Lange ECM, Breimer DD, de Boer AG, Workel JO, De Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998; 139: 1789–1793. 47 Seckl JR, Dickson KL, Yates C, Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res 1991; 561: 332–337. 48 Dodt C, Kern W, Fehm HL, Born J. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus–pituitary–adrenocortical (HPA) axis in humans. Neuroendocrinology 1993; 58: 570–574. 49 Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. The role of mineralocorticoid receptors in hypothalamic–pituitary–adrenal axis regulation in humans. J Clin Endocrinol Metab 1998; 83: 3339–3345. 50 Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F. Increased activity of the hypothalamus–pituitary–adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000; 25: 513–518. 51 Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucose intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab 2001; 86: 1149–1153. 52 Walker BR, Best R, Shackleton CHL, Padfield PL, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996; 27: 190–196. 53 Panarelli M, Holloway CD, Fraser R et al. Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab 1998; 83: 1846–1852. 54 Weaver JU, Hitman GA, Kopelman PG. An association between Bcl 1 restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J Mol Endocrinol 1992; 9: 295–300. 55 Whorwood CB, Donovan SJ, Wood PJ, Phillips DIW. Regulation of glucocorticoid receptor alpha and beta isoforms and type 1 11 beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endo Metab 2001; 86: 2296–2308. 56 McCormick JA, Lyons V, Jacobson MD et al. 5′-heterogeneity of glucocorticoid receptor messenger RNA is tissue specific: differential regulation of variant transcripts by early-life events. Mol Endocrinol 2000; 14: 506–517. 57 MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151–196. 58 Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995; 136: 4754–4761. 59 Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995; 80: 3155–3159. 60 Kotelevtsev Y, Holmes MC, Burchell A et al. 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94: 14924–14929. 61 Livingstone DE, Jones GC, Smith K et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560–563. 62 Rask E, Olsson T, Soderberg S et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418–1421. Citing Literature Volume5, Issue1January 2003Pages 5-12 ReferencesRelatedInformation